Overview

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Status:
Terminated

Trial end date:
2014-11-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Albumin-Bound Paclitaxel
Aromatase Inhibitors
Carboplatin
Cyclophosphamide
Docetaxel
Doxorubicin
Epirubicin
Fluorouracil
Liposomal doxorubicin
Paclitaxel
Trastuzumab